WuXi Biologics stock falls 4.94 percent on October 8, 2026??

Published on 10/08/2026 at 09:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

WuXi Biologics stock traded at HKD 53.90 on October 8, 2026, after first-half revenue reached CNY 11.8 billion. Guidance rose to 20 percent to 23 percent.

WuXi Biologics, KYG970081173, Illustration mit AI erstellt.

WuXi Biologics stock (ISIN KYG970081173) was trading at HKD 53.90 on the Hong Kong Stock Exchange at 3:38 p.m. HKT on October 8, 2026, down HKD 2.80 or 4.94 percent from the prior close. The session range was HKD 53.85 to HKD 57.25, with 30,956,134 shares traded, giving investors a sharp market counterpoint to the company's latest operating update.

First-half growth stayed broad

WuXi Biologics reported first-half 2026 revenue of CNY 11.8 billion, up 18.4 percent from the same period in 2025, according to Yahoo Finance in its August 26, 2026 transcript. On a constant-currency basis, growth reached 23.4 percent, creating a quantified gap of 5.0 percentage points versus the reported-currency increase.

The same transcript showed gross margin at 46.2 percent in the six months ended June 30, 2026, up 350 basis points year over year. Adjusted gross margin reached 48.4 percent, while IFRS net profit increased 5.8 percent to CNY 2.9 billion.

Guidance moved higher

Management raised 2026 constant-currency revenue guidance to 20 percent to 23 percent from 16 percent to 20 percent, according to Yahoo Finance. The lower end of the new range is 4 percentage points above the previous lower end, while the upper end is 3 percentage points higher.

The growth mix also matters. The company said adjusted EBITDA rose 24.9 percent in the first half, and positive free cash flow reached CNY 1.5 billion, according to Yahoo Finance. That combination places margin expansion and cash conversion alongside revenue growth in the current investor debate.

Stock remains below yearly high

At HKD 53.90, the stock was HKD 4.10 below its 52-week high of HKD 58.00 and HKD 25.42 above its 52-week low of HKD 28.48 on October 8, 2026. WuXi Biologics had a market capitalization of HKD 223.3 billion at the same time, so the current move takes place near the top of its yearly trading range rather than after a prolonged decline.

For investors, the central test is execution. Higher guidance and a 48.4 percent adjusted gross margin support the growth case, while the 4.94 percent session decline shows that strong operating figures do not remove short-term valuation and policy sensitivity.